PerioTrap Pharmaceuticals GmbH

PerioTrap Pharmaceuticals GmbH is a Germany-based startup specializing in the development of innovative anti-infective drugs for the curative treatment of periodontitis, an inflammatory gum disease caused by specific bacteria. This condition affects around 30% of the global population and is associated with a range of comorbidities. The lack of an effective treatment in the market spurred the need for PerioTrap's approach. The company's focus lies in the development of locally applied small molecule drugs that selectively target pathogens within the biological flora of the dental pocket, without affecting the protective biofilm. This method aims to prevent the reoccurrence of periodontitis by eradicating the root of the disease, ultimately restoring patient confidence. Established in 2018, the startup recently secured a Seed Round investment on October 21, 2020 from bmp Ventures. The company operates in the Biotechnology and Pharmaceutical industries, with a primary focus on addressing a pertinent global health issue.